Market closed
Novavax/NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Ticker
NVAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,543
Website
Novavax Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$2.28
EPS
1.97
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
1.97
52-week high
$23.86
52-week low
$3.53
Average daily volume
7.2M
Financial strength
Current ratio
1.039
Quick ratio
0.934
Long term debt to equity
-58.862
Total debt to equity
-61.045
Interest coverage (TTM)
-18.79%
Management effectiveness
Return on assets (TTM)
-10.21%
Return on equity (TTM)
49.63%
Valuation
Price to revenue (TTM)
1.295
Price to book
-3.67
Price to tangible book (TTM)
-2.86
Price to free cash flow (TTM)
-54.284
Growth
Revenue change (TTM)
-38.17%
Earnings per share change (TTM)
-67.56%
3-year revenue growth (CAGR)
-5.81%
3-year earnings per share growth (CAGR)
-45.15%
What the Analysts think about Novavax
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Novavax Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Novavax Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Novavax News
AllArticlesVideos
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm
GlobeNewsWire·3 days ago
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
Accesswire·3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $1.6B as of October 26, 2024.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of October 26, 2024.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.